Company intelligence / Profile preview

GynTools

Jerusalem, Jerusalem District, Israelgyntools.com ↗

Ownership: Private
Employees: ~20
Development stage: Other

Overview

GynTools has developed and commercialized "Gyni," an AI-powered point-of-care device that diagnoses all seven major causes of vaginitis—both infectious and non-infectious—with 95% accuracy within five minutes. The product is CE-marked for Europe, AMAR-certified in Israel, ISO 13485 certified, and is currently undergoing clinical trials to support FDA clearance for the US market. Early results indicate high accuracy and significant potential to reduce misdiagnosis rates[1][2][3].

Therapeutic areas: Women's Health
Modalities: DeviceArtificial intelligence (AI)Machine learning-based diagnostic systemNon-pharmacological therapy (diagnostic only)
Industry: Digital Health Medical Devices

Partnerships

No specific pharmaceutical or biotech partnerships disclosed as of June 2025.

Beyond the preview

Go deeper on GynTools.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GynTools.

Explore the full profile